Charles Schwab’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Charles Schwab’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,509	Closed	-$23K	–	3726
2022 Q1	$23K	Hold	4,509	–	–	﹤0.01%	3575
2021 Q4	$26K	Hold	4,509	–	–	﹤0.01%	3571
2021 Q3	$50K	Hold	4,509	–	–	﹤0.01%	3452
2021 Q2	$77K	Sell	4,509 -8,568	-66%	-$162K	﹤0.01%	3314
2021 Q1	$344K	Sell	13,077 -454	-3%	-$20.6K	﹤0.01%	3208
2020 Q4	$490K	Hold	13,531	–	–	﹤0.01%	3000
2020 Q3	$480K	Buy	13,531 +6,447	+91%	+$280K	﹤0.01%	2884
2020 Q2	$301K	Buy	7,084 +5,122	+261%	+$345K	﹤0.01%	3046
2020 Q1	$157K	Hold	1,962	–	–	﹤0.01%	3056
2019 Q4	$182K	Hold	1,962	–	–	﹤0.01%	3051
2019 Q3	$149K	Sell	1,962 -1,005	-34%	-$77.2K	﹤0.01%	3075
2019 Q2	$296K	Buy	+2,967	New	+$230K	﹤0.01%	3008

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Charles Schwab's EVFM Position: Q2 2022 in Review

Charles Schwab sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 4,509 shares — an estimated $23K sold.

Charles Schwab first reported a position in EVFM in Q2 2019 and held it in 12 quarters. The position peaked at $490K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Charles Schwab reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Charles Schwab sold 4,509 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $23K.
Charles Schwab first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Charles Schwab's Evofem Biosciences, Inc. Common Stock position peaked at $490K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.